Cross-Sector entity
Novartis is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. clinical-trial accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. TLX591 appears in 2 tracked Cross-Sector stories from March 10, 2026.
2 verified stories tracked
Last mentioned: Mar 10, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Novartis is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. clinical-trial accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. TLX591 appears in 2 tracked Cross-Sector stories from March 10, 2026. The tracked stories average 4 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering TLX591. Shared-story counts are live from our verified record — not editorial picks.
Interim Analysis
Expected interim efficacy data from the larger global patient cohort.
Part 2 Expansion
Full global enrollment for efficacy endpoints (rPFS and OS) expected to accelerate.
Primary Objectives Met
Announcement that Part 1 successfully validated safety and dosimetry profiles.
Part 1 Completion
Enrollment for the safety and dosimetry portion of the study concludes.
Enrollment Milestone
Completion of patient enrollment for the Part 1 SELECT lead-in phase.
Study Initiation
Launch of the ProstACT Global Phase 3 study for mCRPC.
Telix Pharmaceuticals has announced that Part 1 of its ProstACT GLOBAL Phase 3 study for TLX591 successfully met its primary objectives. This milestone confirms the safety and dosimetry of the company's lead radiopharmaceutical candidate for metastatic prostate cancer, clearing the way for full trial expansion.
Telix Pharmaceuticals has successfully met the primary objectives for Part 1 of its global Phase 3 ProstACT study, validating the safety and dosimetry of its lead therapeutic candidate, TLX591. This milestone de-risks the antibody-based radiopharmaceutical program and clears the path for the trial's continued expansion in metastatic castration-resistant prostate cancer.
Source: sydneysun.com · wallstreet-online.de
